Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 11/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 10/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | FABP3 | P05413 | 2/20 | 0.37 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978428 | 0.89 | SCN9A (0.39) | SCN9ASLC6A9SCN7ASCN5A | |
| SCHEMBL977534 | 0.87 | SCN9A (0.40) | SCN9ASLC6A9SCN7ASCN5A | |
| SCHEMBL977533 | 0.87 | SCN9A (0.40) | SCN9ASLC6A9SCN7ASCN5A | |
| SCHEMBL975708 | 0.85 | SCN9A (0.38) | SCN9ASCN7ASCN5A | |
| SCHEMBL977177 | 0.85 | SCN9A (0.38) | SCN9ASCN7ASCN5A | |
| SCHEMBL977993 | 0.83 | SCN9A (0.37) | SCN9ASCN7ASCN5A | |
| SCHEMBL976851 | 0.83 | SCN9A (0.38) | SCN9ASLC6A9SCN7ASCN5A | |
| SCHEMBL974202 | 0.83 | WDR5 (0.41) | FABP4SCN9ASLC6A9SCN7ASCN5A | |
| SCHEMBL977461 | 0.83 | MEN1 (0.44) | SLC6A9 | |
| SCHEMBL976064 | 0.82 | ACLY (0.43) | FABP4SCN9ASLC6A9SCN7ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | claimed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | FABP4 4872/4885FABP5 4777/4885SCN9A 694/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | FABP4 4872/4885FABP5 4777/4885SCN9A 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.